Modulation of GH/IGF-1 axis: Potential strategies to counteract sarcopenia in older adults
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Aging is associated with progressive decline of skeletal muscle mass and function. This condition, termed sarcopenia, is associated with several adverse outcomes, including loss of autonomy and mortality. Due to the high prevalence of sarcopenia, a deeper understanding of its pathophysiology and possible remedies represents a high public health priority. Evidence suggests the existence of a relationship between declining growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels and age-related changes in body composition and physical function. Therefore, the age-dependent decline of GH and IGF-1 serum levels may promote frailty by contributing to the loss of muscle mass and strength. Preclinical studies showed that infusion of angiotensin II produced a marked reduction in body weight, accompanied by decreased serum and muscle levels of IGF-1. Conversely, overexpression of muscle-specific isoform of IGF-1 mitigates angiotensin II-induced muscle loss. Moreover, IGF-1 serum levels have been shown to increase following angiotensin converting enzyme inhibitors (ACEIs) treatment. Here we will review the most recent evidence regarding age-related changes of the GH/IGF-1 axis and its modulation by several interventions, including ACEIs which might represent a potential novel strategy to delay the onset and impede the progression of sarcopenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stitt, T. N., Drujan, D., Clarke, B. A., Panaro, F., Timofeyva, Y., Kline, W. O., Gonzalez, M., Yancopoulos, G. D., & Glass, D. J. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00211-4 · Cited by 1,964
Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression
Lecker, S. H., Jagoe, R. T., Gilbert, A., Gomes, M., Baracos, V., Bailey, J., Price, S. R., Mitch, W. E., & Goldberg, A. L. (2004) · The FASEB Journal · doi:10.1096/fj.03-0610com · Cited by 1,539 · cited 2×
“Atrogin-1 and MuRF-1 are musclespecific proteins of the ubiquitin-proteasome pathway, which are dramatically induced in various models of muscle atrophy (Lecker et al., 2004) via the phosphatidylinositol 3-kinase (PI3K)/Akt pathway (Stitt et al.”
BackgroundAssociations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly
Harris, T. B., Ferrucci, L., Tracy, R. P., Corti, M. C., Wacholder, S., Ettinger, W. H., Heimovitz, H., Cohen, H. J., & Wallace, R. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00066-2 · Cited by 1,488 · cited 1×
“IL-6 is a pro-inflammatory cytokine upregulated with age (Ershler and Keller, 2000), that has been associated with increased mortality (Harris et al., 1999) and disability (Ferrucci et al., 1999) in the elderly.”
BackgroundVisser, M., Pahor, M., Taaffe, D. R., Goodpaster, B. H., Simonsick, E. M., Newman, A. B., Nevitt, M., & Harris, T. B. (2002) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/57.5.m326 · Cited by 1,294
Age-Associated Increased Interleukin-6 Gene Expression, Late-Life Diseases, and Frailty
Ershler, W. B., & Keller, E. T. (2000) · Annual Review of Medicine · doi:10.1146/annurev.med.51.1.245 · Cited by 1,282 · cited 1×
“IL-6 is a pro-inflammatory cytokine upregulated with age (Ershler and Keller, 2000), that has been associated with increased mortality (Harris et al., 1999) and disability (Ferrucci et al., 1999) in the elderly.”
BackgroundMusarò, A., McCullagh, K., Paul, A., Houghton, L., Dobrowolny, G., Molinaro, M., Barton, E. R., L Sweeney, H., & Rosenthal, N. (2001) · Nature Genetics · doi:10.1038/84839 · Cited by 1,137 · cited 2×
“…systemic administration of IGF-1 results in controversial findings on muscle strength and function, transgenic overexpression of IGF-1 has been shown to exert beneficial effects on skeletal muscle (Musaro et al., 2001; Barton et al., 2002; Gregorevic et al., 2002, 2004; Schertzer et al., 2006).”
BackgroundTestosterone dose-response relationships in healthy young men
Bhasin, S., Woodhouse, L., Casaburi, R., Singh, A. B., Bhasin, D., Berman, N., Chen, X., Yarasheski, K. E., Magliano, L., Dzekov, C., et al. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.6.e1172 · Cited by 967 · cited 2×
“, 2001), testosterone (Bhasin et al., 2001), and muscle overload and stretch (Goldspink et al.”
BackgroundSerum IL‐6 Level and the Development of Disability in Older Persons
Ferrucci, L., Harris, T. B., Guralnik, J. M., Tracy, R. P., Corti, M., Cohen, H. J., Penninx, B., Pahor, M., Wallace, R., & Havlik, R. J. (1999) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1999.tb01583.x · Cited by 809
Coleman, M. E., DeMayo, F., Yin, K. C., Lee, H. M., Geske, R., Montgomery, C., & Schwartz, R. J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.20.12109 · Cited by 642
Growth Hormone Replacement in Healthy Older Men Improves Body Composition but Not Functional Ability
Papadakis, M. A., Grady, D., Black, D., Tierney, M. J., Gooding, G. A. W., Schambelan, M., & Grunfeld, C. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-8-199604150-00002 · Cited by 474
Cited by
Sarcopenia: etiology, clinical consequences, intervention, and assessment
Lang, T., Streeper, T., Cawthon, P., Baldwin, K., Taaffe, D. R., & Harris, T. B. (2010) · Osteoporosis International · doi:10.1007/s00198-009-1059-y · Cited by 777
Mitochondrial dysfunction and sarcopenia of aging: from signaling pathways to clinical trials
Marzetti, E., Calvani, R., Cesari, M., Buford, T. W., Lorenzi, M., Behnke, B. J., & Leeuwenburgh, C. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.06.024 · Cited by 627
Self-citationSarcopenia, frailty and their prevention by exercise
Nascimento, C. M., Ingles, M., Salvador-Pascual, A., Cominetti, M. R., Gomez-Cabrera, M. C., & Viña, J. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.08.035 · Cited by 396
Yoshimura, Y., Wakabayashi, H., Yamada, M., Kim, H., Harada, A., & Arai, H. (2017) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2017.03.019 · Cited by 365
Sinclair, M., Gow, P. J., Grossmann, M., & Angus, P. W. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13549 · Cited by 316
Biological effects of growth hormone on carbohydrate and lipid metabolism
Vijayakumar, A., Novosyadlyy, R., Wu, Y., Yakar, S., & LeRoith, D. (2010) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2009.09.002 · Cited by 300
Sarcopenia: assessment of disease burden and strategies to improve outcomes
Liguori, I., Russo, G., Aran, L., Bulli, G., Curcio, F., Della-Morte, D., Gargiulo, G., Testa, G., Cacciatore, F., Bonaduce, D., et al. (2018) · Clinical Interventions in Aging · doi:10.2147/cia.s149232 · Cited by 300
Volpato, S., Bianchi, L., Cherubini, A., Landi, F., Maggio, M., Savino, E., Bandinelli, S., Ceda, G. P., Guralnik, J. M., Zuliani, G., et al. (2014) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glt149 · Cited by 297
Li, C., Yu, K., Shyh‐Chang, N., Li, G., Jiang, L., Yu, S., Xu, L., Liu, R., Guo, Z., Xie, H., et al. (2019) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12417 · Cited by 280
Arterial stiffness is associated with low thigh muscle mass in middle-aged to elderly men
Ochi, M., Kohara, K., Tabara, Y., Kido, T., Uetani, E., Ochi, N., Igase, M., & Miki, T. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.05.026 · Cited by 252
Sarcopenic obesity and endocrinal adaptation with age
Sakuma, K., & Yamaguchi, A. (2013) · International Journal of Endocrinology · doi:10.1155/2013/204164 · Cited by 189
“Sarcopenic obesity appears to be linked with the upregulation of TNF-𝛼, interleukin (IL)-6, leptin, and myostatin and the downregulation of adiponectin and IL-15.”
BackgroundSarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass
Sakuma, K., & Yamaguchi, A. (2012) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1007/s13539-011-0052-4 · Cited by 137
Luque, R. M., Lin, Q., Córdoba-Chacón, J., Subbaiah, P. V., Buch, T., Waisman, A., Vankelecom, H., & Kineman, R. D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015767 · Cited by 73
“Therefore, multiple studies have been conducted to examine the impact of GH replacement in elderly and obese individuals [4–6] and off-label use and abuse of GH is becoming more prevalent in healthy adults to enhance body image and athletic performance.”
PGC-1α and Myokines in the Aging Muscle – A Mini-Review
Arnold, A.-S., Egger, A., & Handschin, C. (2011) · Gerontology · doi:10.1159/000281883 · Cited by 65
Yeap, B. B., Paul Chubb, S. A., Lopez, D., Ho, K. K. Y., Hankey, G. J., & Flicker, L. (2013) · Clinical Endocrinology · doi:10.1111/cen.12052 · Cited by 53
“IGF-I mediates growth and repair in skeletal muscle, hence the expectation that lower IGF-I levels might predispose to frailty (for review, see [19]).”
Metadata
- Authors
- Giovannini, S., Marzetti, E., Borst, S. E., & Leeuwenburgh, C.
- Venue
- Mechanisms of Ageing and Development
- Publisher
- Elsevier BV
- Published
- 2008-10
- Volume
- 129
- Issue
- 10
- Pages
- 593-601
- ISSN
- 0047-6374 (ISSN-L)
- OpenAlex
- W1977037979
- Cited by
- 136
- References
- 17
- FWCI
- 6.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.